The Potential of Plasminogen Activator Inhibitor-1 as Prognostic Factor of Advanced Breast Cancer
Advances in Hematology and Oncology Research · 2020
DOI: 10.33140/ahor.03.01.09 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Hematology and Oncology Research, 2020.
Abstract (Originalsprache)
Background
Advanced breast cancer causes problems in morbidity, mortality, quality of life, and low survival rate. Hence, a biomarker to predict the progression of cancer is needed. Plasminogen activator inhibitor-1 (PAI-1) has been known as one of the prognostic factors. However, in vivo studies indicated that PAI-1 has controversial roles. Whether PAI-1 suppresses or promotes the development of cancer, is still being the question. The study aims to examine the role of PAI-1 in predicting the survival rate and its association with clinicopathologic factors in advanced breast cancer. Materials and Methods: The historical cohort analytic method in advanced breast cancer patients was conducted at Dharmais National Cancer Center Hospital. Clinical data were obtained from patients’ medical records. The expression of PAI-1 was assessed through immunohistochemistry assay staining of breast cancer tissue using antibody PAI-1 Santa Cruz Biotechnology, Inc., PAI-1 C-9 sc5297. Survival analysis was done to obtain the prognostic data. Moreover, its association with clinicopathologic factors was analyzed.
Results
Fifty-eight subjects were included in this study. There was a significant association between the expression of PAI-1 and survival rate (hazard ratio [HR] = 4.08, 95% confidence interval [CI] = 1.75 - 9.50, p = 0.001). The Kaplan-Meier method indicated significant differences in survival rate between subjects with high expression of PAI1 and those with low expression in advanced breast cancer (p = 0.001). PAI-1 expression had a sensitivity of 84.7% and specificity of 60% based on immunohistochemical score cut off of 90. Furthermore, the expression of PAI-1 showed no significant association with clinicopathological factors except for histopathology grade. (Relative risk [RR] = 1.5, 95%, CI = 1.2 - 1.8, p = 0.047).
Conclusion
Advanced breast cancer patients with high expression of PAI-1 have better survival. PAI-1 expression is not associated with clinicopathological factors, except for the histopathological grade.
Zitieren
APA
(2020). The Potential of Plasminogen Activator Inhibitor-1 as Prognostic Factor of Advanced Breast Cancer. Advances in Hematology and Oncology Research. https://doi.org/10.33140/ahor.03.01.09
Vancouver
The Potential of Plasminogen Activator Inhibitor-1 as Prognostic Factor of Advanced Breast Cancer. Advances in Hematology and Oncology Research. 2020. doi:10.33140/ahor.03.01.09
BibTeX
@article{euvimed2020,
title = {The Potential of Plasminogen Activator Inhibitor-1 as Prognostic Factor of Advanced Breast Cancer},
journal = {Advances in Hematology and Oncology Research},
year = {2020},
doi = {10.33140/ahor.03.01.09}
}
EUVIMED